GlassScriptPhysician profile
Hans H Kim
NPI 1710093182
$9,525.04
in general payments reported to CMS, 2019-2025
31 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 82% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2020: $840 · 2021: $1,302 · 2022: $1,211 · 2023: $890 · 2024: $1,756 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,313 · Travel and Lodging: $1,040 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.52 |
| Travel and Lodging | $1,040.09 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,040.09 | 2024 | Spaceoar System |
| Aerie Pharmaceuticals, INC. | $837.77 | 2019-2021 | |
| Allergan, INC. | $807.71 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $802.19 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $778.61 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $766.42 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $531.37 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $521.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $474.92 | 2019-2022 | |
| Alcon Vision LLC | $437.90 | 2019-2025 | Rocklatan, Argos, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $295.74 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $276.88 | 2020-2023 | Eylea Hd |
| Oyster Point Pharma, INC. | $211.23 | 2022-2025 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $197.36 | 2021-2022 | |
| Akorn Operating Company LLC | $176.01 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $155.74 | 2019 | |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Akorn, INC. | $143.75 | 2019-2020 | |
| Dompe US, INC. | $143.69 | 2022-2025 | Oxervate |
| Thea Pharma INC. | $141.74 | 2022-2025 | Iyuzeh |
| Amgen INC. | $120.79 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $100.21 | 2019-2023 | Flarex |
| Nova Eye, INC. | $99.50 | 2025 | |
| Kala Pharmaceuticals, INC. | $71.77 | 2021-2022 | |
| Genentech USA, INC. | $50.39 | 2023-2024 | Vabysmo |
| Glaukos Corporation | $49.34 | 2021-2023 | |
| Alimera Sciences, INC. | $46.44 | 2019-2021 | |
| Harrow Eye, LLC | $27.62 | 2025 | Vevye |
| Optos, INC. | $24.89 | 2022 | |
| Topcon Healthcare Solutions, INC. | $24.54 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.